BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190331
DTEND;VALUE=DATE:20190502
DTSTAMP:20260730T052114
CREATED:20190331T183936Z
LAST-MODIFIED:20190331T183936Z
UID:21151-1553990400-1556755199@ces.b2sg.org
SUMMARY:Oncology Medical Science Liaisons
DESCRIPTION:Are you interested in being a part of an exciting new Oncology MSL launch team?  GSK is hiring in the following territories! We are looking for motivated individuals who want to be a part of an amazing culture that fosters growth and help build a team from the ground up.  At least 2 years of oncology MSL experience is required along with an advanced degree (PharmD\, PhD\, MD).  \n\nMSL Oncology (Rochester\, MN/Minneapolis\, MN) \n\nhttps://gsk.wd5.myworkdayjobs…. \n\nMSL Oncology (Baltimore\, MD/Washington\, DC) \n\nhttps://gsk.wd5.myworkdayjobs…. \n\nMSL Oncology (New York\, NY) \n\nhttps://gsk.wd5.myworkdayjobs…. \n\n\nMSL Oncology (Nashville\, TN) \n\nhttps://gsk.wd5.myworkdayjobs…. \n\nMSL Oncology (Columbus\, OH/Cleveland\, OH) \n\nhttps://gsk.wd5.myworkdayjobs…. \n\nMSL Oncology (Boston\, MA) \n\nhttps://gsk.wd5.myworkdayjobs…. \n\nGSK Oncology is committed to the discovery and development of new and potentially life-changing therapies for patients with cancer. Our vision is for people with cancer to not only to live\, but to live well\, because we are delivering innovative and transformational medicines.  We have strictly focused our portfolio on innovation with a focus on the leading edges of science: immuno-oncology\, cell therapy and epigenetics.  Our deep insight into cancer biology coupled with strategic partnerships will allow us to develop synergistic combinations with transformational potential.    \nOn December 3\, 2018 we announced our agreement to acquire TESARO\, an oncology-focused company based in the US.  The proposed transaction will significantly strengthen our pharmaceutical business\, accelerating the build of our pipeline and commercial capability in oncology.
URL:https://ces.b2sg.org/event/gsk31mar19/
LOCATION:gsk\, 1250 S Collegeville Rd\, Collegeville\, PA\, 19426\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/10/GSK-1-e1507913461300.jpg
END:VEVENT
END:VCALENDAR